S R Schwid

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. ncbi request reprint Quantitative functional measures in MS: what is a reliable change?
    S R Schwid
    Department of Neurology, University of Rochester Medical Center, NY, USA
    Neurology 58:1294-6. 2002
  2. ncbi request reprint Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
  3. ncbi request reprint Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 65:1964-6. 2005
  4. ncbi request reprint Cognitive fatigue during a test requiring sustained attention: a pilot study
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 9:503-8. 2003
  5. ncbi request reprint Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Arch Neurol 62:785-92. 2005
  6. pmc Quantitative risk-benefit analysis of natalizumab
    J P Thompson
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 71:357-64. 2008
  7. ncbi request reprint Neuropsychologic status in multiple sclerosis after treatment with glatiramer
    A Weinstein
    Department of Neurology, University of Rochester Medical Center, NY 14642, USA
    Arch Neurol 56:319-24. 1999
  8. pmc Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study
    K Noyes
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
    Neurology 77:355-63. 2011
  9. doi request reprint Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Andrew D Goodman
    University of Rochester, Rochester, NY, USA
    Lancet 373:732-8. 2009
  10. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008

Detail Information

Publications31

  1. ncbi request reprint Quantitative functional measures in MS: what is a reliable change?
    S R Schwid
    Department of Neurology, University of Rochester Medical Center, NY, USA
    Neurology 58:1294-6. 2002
    ..Therefore, a 20% change on these tests can be considered to be the threshold that reliably indicates a true change in function for an individual...
  2. ncbi request reprint Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial
    Steven R Schwid
    University of Rochester, Department of Neurology, Rochester, NY 14642, USA
    J Neurol Sci 255:57-63. 2007
    ....
  3. ncbi request reprint Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 65:1964-6. 2005
    ..The two groups were similar in the proportion of patients achieving an HI titer of 40 or greater, the prespecified primary end point and on all secondary indicators of immune response...
  4. ncbi request reprint Cognitive fatigue during a test requiring sustained attention: a pilot study
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 9:503-8. 2003
    ..Motor fatigue can be objectively measured as the decline in strength occurring during sustained contractions. Analogous declines in cognitive performance occur during tasks requiring sustained attention...
  5. ncbi request reprint Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Arch Neurol 62:785-92. 2005
    ....
  6. pmc Quantitative risk-benefit analysis of natalizumab
    J P Thompson
    Department of Neurology, University of Rochester, Rochester, NY, USA
    Neurology 71:357-64. 2008
    ..To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS)...
  7. ncbi request reprint Neuropsychologic status in multiple sclerosis after treatment with glatiramer
    A Weinstein
    Department of Neurology, University of Rochester Medical Center, NY 14642, USA
    Arch Neurol 56:319-24. 1999
    ..Glatiramer acetate (Copaxone) therapy reduces clinical disease activity in relapsing-remitting multiple sclerosis (MS)...
  8. pmc Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study
    K Noyes
    Department of Community and Preventive Medicine, University of Rochester, 601 Elmwood Ave, Box 644, Rochester, NY 14620, USA
    Neurology 77:355-63. 2011
    ..To evaluate the cost-effectiveness of disease-modifying therapies (DMTs) in the United States compared to basic supportive therapy without DMT for patients with relapsing multiple sclerosis (MS)...
  9. doi request reprint Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial
    Andrew D Goodman
    University of Rochester, Rochester, NY, USA
    Lancet 373:732-8. 2009
    ..This phase III study assessed efficacy and safety of oral, sustained-release fampridine in people with ambulatory deficits due to multiple sclerosis...
  10. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  11. pmc GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study
    A D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Neurology 72:806-12. 2009
    ..The primary outcome assessed whether this combination would increase the rate of development of new active lesions on cranial MRI scans vs GA alone...
  12. ncbi request reprint Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
    J A Cohen
    Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Cleveland Clinic Foundation, OH 44195, USA
    J Neuroimmunol 98:29-36. 1999
    ..Neurologists managing patients on disease-modifying therapy for R-MS must remain vigilant for these issues and take appropriate action when necessary...
  13. doi request reprint A phase 3 trial of extended release oral dalfampridine in multiple sclerosis
    Andrew D Goodman
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Ann Neurol 68:494-502. 2010
    ..The current study was designed to confirm efficacy and further define safety and pharmacodynamics...
  14. doi request reprint Broadening the spectrum of controls for skin biopsy in painful neuropathies
    David N Herrmann
    Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    Muscle Nerve 42:436-8. 2010
    ..Distal-leg ENFD/morphology in MS DLLBP patients did not differ significantly from that of healthy controls. This study extends the range of ENFD controls and further supports use of ENFD assessment in SFSN...
  15. doi request reprint Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, University of Rochester Medical Center, 601 Elmwood Avenue, Box 605, Rochester, NY 14586, USA
    Nat Clin Pract Neurol 5:82-92. 2009
    ..We propose that the potential role of PUFAs as disease-modifying, anti-inflammatory treatments for MS should be revisited in proof-of-concept trials that use accepted MRI outcome measures...
  16. ncbi request reprint Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relap
    Steven R Schwid
    Department of Nuerology, University of Rochester, Rochester, New York 14642, USA
    Clin Ther 29:2031-48. 2007
    ..Interferon (IFN)-beta therapy represents an important advance in the management of relapsing multiple sclerosis (MS), but information about the relative benefits and risks of available preparations is limited...
  17. doi request reprint Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Mult Scler 14:425-7. 2008
    ....
  18. ncbi request reprint Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
    Neurology 68:1524-8. 2007
    ..033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days)...
  19. pmc Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis
    L B Krupp
    Department of Neurology, State University of New York at Stony Brook, Stony Brook, NY 11794 8121, USA
    Neurology 76:1500-7. 2011
    ..The goal of this study was to determine if memory would be improved by donepezil as compared to placebo in a multicenter, double-blind, randomized clinical trial (RCT)...
  20. doi request reprint A randomized trial of memantine as treatment for spasticity in multiple sclerosis
    Lahar R Mehta
    Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Mult Scler 16:248-51. 2010
    ..The primary outcome measure for efficacy was the change in Ashworth Spasticity Scale Score. Although well tolerated, memantine treatment did not demonstrate efficacy in treatment of spasticity in this 12-week small exploratory study...
  21. ncbi request reprint A randomized controlled study of the acute and chronic effects of cooling therapy for MS
    Steven R Schwid
    University of Rochester, Rochester, NY, USA
    Neurology 60:1955-60. 2003
    ....
  22. doi request reprint Proof of concept studies for tissue-protective agents in multiple sclerosis
    L R Mehta
    University of Rochester Department of Neurology, Rochester, NY, USA
    Mult Scler 15:542-6. 2009
    ..There is considerable interest in tissue-protective treatments for multiple sclerosis (MS)...
  23. ncbi request reprint Fatigue in multiple sclerosis: current understanding and future directions
    Steven R Schwid
    Department of Neurology, University of Rochester Medical Center, NY, USA
    J Rehabil Res Dev 39:211-24. 2002
    ..Dividing fatigue into these components can provide objective assessments that are less likely to be confounded by other symptoms of MS, such as weakness, spasticity, cognitive impairment, and depressed mood...
  24. doi request reprint Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...
  25. doi request reprint Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease
    Steven R Schwid
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Mov Disord 25:1801-8. 2010
    ..Melanoma occurrence in our PD patients was greater than predicted compared with the general population and was unrelated to dopaminergic therapy. Clinical surveillance of PD patients for melanoma may be warranted...
  26. ncbi request reprint Pain associated with multiple sclerosis: systematic review and proposed classification
    Alec B O'Connor
    Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Pain 137:96-111. 2008
    ..Suggestions for future studies that would increase understanding of the natural history, mechanisms, and treatment of pain in patients with MS are presented...
  27. ncbi request reprint Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline
    J Antonelle deMarcaida
    Department of Neurology, University of Connecticut, Farmington, Connecticut, USA
    Mov Disord 21:1716-21. 2006
    ..These data demonstrate that rasagiline 0.5 to 2 mg daily is not associated with clinically significant tyramine reactions and can be used as monotherapy or adjunct to levodopa in PD patients without specific dietary tyramine restriction...
  28. pmc Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
    Michael A Schwarzschild
    MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, USA
    Arch Neurol 65:716-23. 2008
    ..To determine whether concentration of serum urate, a purine metabolite and potent antioxidant that has been linked to a reduced risk of Parkinson disease (PD), predicts prognosis in PD...
  29. ncbi request reprint Treating fatigue in patients with MS: one step forward, one step back
    Steven R Schwid
    Neurology 64:1111-2. 2005
  30. ncbi request reprint Futility studies: spending a little to save a lot
    Steven R Schwid
    Neurology 66:626-7. 2006
  31. ncbi request reprint Multiple sclerosis, depression, and the risk of suicide
    Eric D Caine
    Neurology 59:662-3. 2002